Science News
from research organizations

Harnessing anticancer drugs for the future fight against influenza

Date:
September 5, 2012
Source:
Helsingin yliopisto (University of Helsinki)
Summary:
Researchers in Finland have developed a new cell screening method that can be used to identify potential anti-influenza drugs. They also identified two novel anti-influenza agents.
Share:
       
FULL STORY

In search for novel antivirals, a total of 201 host-directed compounds were tested for their antiviral efficacy.
Credit: Photographer Oxana Denisova, FIMM

Researchers at the Institute for Molecular Medicine Finland (FIMM) together with their collaborators have developed a new cell screening method that can be used to identify potential anti-influenza drugs. They also identified two novel anti-influenza agents.

Medical Systems Virology group at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, together with its national and international collaborators, developed a new cell screening method that can be used to identify potential anti-influenza drugs. The researchers were able to identify two novel compounds with anti-influenza activity, obatoclax and gemcitabine and prove the efficacy of a previously known drug saliphenylhalamide. The study was recently accepted for publication in the Journal of Biological Chemistry and is now available online.

Influenza viruses cause significant human morbidity and mortality. To treat the infections, different virus-directed drugs have been developed. However, the currently available drugs are targeting viral proteins and due to a high mutation rate the influenza viruses quickly develop resistance to them. For that reason, next-generation antiviral drugs should be directed towards the host functions. The results of this study provide a foundation for development of next-generation antiviral drugs. Furthermore, these identified compounds can be used as chemical tools when studying the molecular mechanisms of virus-host interactions.

“An interesting aspect of this study is that the antiviral effects of obatoclax, saliphenylhalamide and gemcitabine, which all are either investigational or approved anticancer agents, are achieved at much lower concentrations than that needed to mediate cancer cell death” said the group leader Denis Kainov. However, further research is still needed before these drugs can be clinically tested and applied in influenza infections.

This research project is a good example of repurposing of drugs, i.e. finding new applications for existing drugs and thus saving money and time on drug development.

“We anticipate that these types of drugs could in the future reinforce the therapeutic arsenal and address the needs of the society to control influenza outbreaks”, said Olli Kallioniemi, the Director of FIMM.


Story Source:

The above post is reprinted from materials provided by Helsingin yliopisto (University of Helsinki). Note: Materials may be edited for content and length.


Journal Reference:

  1. O. V. Denisova, L. Kakkola, L. Feng, J. Stenman, A. Nagaraj, J. Lampe, B. Yadav, T. Aittokallio, P. Kaukinen, T. Ahola, S. Kuivanen, O. Vapalahti, A. Kantele, J. Tynell, I. Julkunen, H. Kallio-Kokko, H. Paavilainen, V. Hukkanen, R. M. Elliott, J. K. De Brabander, X. Saelens, D. E. Kainov. Obatoclax, saliphenylhalamide and gemcitabine inhibit influenza A virus infection. Journal of Biological Chemistry, 2012; DOI: 10.1074/jbc.M112.392142

Cite This Page:

Helsingin yliopisto (University of Helsinki). "Harnessing anticancer drugs for the future fight against influenza." ScienceDaily. ScienceDaily, 5 September 2012. <www.sciencedaily.com/releases/2012/09/120905083903.htm>.
Helsingin yliopisto (University of Helsinki). (2012, September 5). Harnessing anticancer drugs for the future fight against influenza. ScienceDaily. Retrieved July 31, 2015 from www.sciencedaily.com/releases/2012/09/120905083903.htm
Helsingin yliopisto (University of Helsinki). "Harnessing anticancer drugs for the future fight against influenza." ScienceDaily. www.sciencedaily.com/releases/2012/09/120905083903.htm (accessed July 31, 2015).

Share This Page: